(CCAP) Crescent Capital BDC - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2256551092

Stock: Private, Equity, Buyouts, Loans, Middle-Market

Total Rating 27

Risk 84

Buy Signal -0.91

Asset Management » Asset Management & Custody Banks
Age: 6y

Market Cap: 532m
Avg Trading Vol: 2.18M USD

ATR: 2.26%
Peers RS (IBD): 37.22

EPS (Earnings per Share)

EPS CAGR: -45.65%
EPS Trend: -33.2%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 23.65%
Rev. Trend: 65.6%

Last SUE: -0.05
Qual. Beats: 0

Dividends

Dividend Yield	12.28%
Yield on Cost 5y	20.18%
Yield CAGR 5y	2.01%
Payout Consistency	98.5%
Payout Ratio	99.2%

Risk 5d forecast
Volatility	21.0%
Relative Tail Risk	-2.30%

Reward TTM
Sharpe Ratio	-0.76
Alpha	-29.72

Character TTM
Beta	0.732
Beta Downside	0.804

Drawdowns 3y
Max DD	27.89%
CAGR/Max DD	0.41

Description: CCAP Crescent Capital BDC December 26, 2025

Crescent Capital BDC, Inc. (NASDAQ: CCAP) is a Business Development Company that operates as a private-equity-focused buyout and loan fund, targeting direct investments in U.S. middle-market companies.

As of the latest filing (Q3 2024), the BDC reported approximately $1.2 billion in assets under management, a net asset value (NAV) per share of $23.40, and a portfolio leverage ratio of roughly 1.2 ×-both metrics that are modest relative to industry averages and suggest a disciplined risk profile. The fund’s performance is closely tied to the health of the U.S. middle-market credit market, which is currently influenced by the Federal Reserve’s policy stance: higher short-term rates tend to compress loan spreads but also increase demand for flexible, senior-secured financing.

If you want a deeper, data-driven view of CCAP’s valuation and risk characteristics, a quick look at ValueRay’s analytical dashboard can help you spot any hidden upside or downside before you decide.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income: 36.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA -3.86 > 1.0
NWC/Revenue: -1.63% < 20% (prev 6.14%; Δ -7.77% < -1%)
CFO/TA 0.02 > 3% & CFO 37.1m > Net Income 36.0m
Net Debt (869.5m) to EBITDA (37.3m): 23.32 < 3
Current Ratio: 0.89 > 1.5 & < 3
Outstanding Shares: last quarter (37.1m) vs 12m ago -0.00% < -2%
Gross Margin: 64.60% > 18% (prev 0.64%; Δ 6396 % > 0.5%)
Asset Turnover: 9.35% > 50% (prev 9.96%; Δ -0.61% > 0%)
Interest Coverage Ratio: 2.30 > 6 (EBITDA TTM 37.3m / Interest Expense TTM 54.2m)

Altman Z'' -0.27

A: -0.00 (Total Current Assets 21.0m - Total Current Liabilities 23.5m) / Total Assets 1.63b
B: -0.15 (Retained Earnings -244.7m / Total Assets 1.63b)
C: 0.08 (EBIT TTM 124.4m / Avg Total Assets 1.64b)
D: -0.27 (Book Value of Equity -244.7m / Total Liabilities 913.6m)
Altman-Z'' Score: -0.27 = B

What is the price of CCAP shares?

As of February 07, 2026, the stock is trading at USD 14.40 with a total of 263,900 shares traded.
Over the past week, the price has changed by +0.07%, over one month by +0.35%, over three months by +6.22% and over the past year by -17.56%.

Is CCAP a buy, sell or hold?

Crescent Capital BDC has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy CCAP.

StrongBuy: 3
Buy: 1
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the CCAP price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	15.8	9.4%
Analysts Target Price	15.8	9.4%
ValueRay Target Price	17.1	18.8%

CCAP Fundamental Data Overview February 02, 2026

P/E Trailing = 14.8351
P/E Forward = 8.9366
P/S = 3.0789
P/B = 0.7455
P/EG = 0.8918
Revenue TTM = 153.0m USD
EBIT TTM = 124.4m USD
EBITDA TTM = 37.3m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 875.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 869.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.40b USD (532.3m + Debt 875.3m - CCE 5.79m)
Interest Coverage Ratio = 2.30 (Ebit TTM 124.4m / Interest Expense TTM 54.2m)
EV/FCF = 37.79x (Enterprise Value 1.40b / FCF TTM 37.1m)
FCF Yield = 2.65% (FCF TTM 37.1m / Enterprise Value 1.40b)
FCF Margin = 24.25% (FCF TTM 37.1m / Revenue TTM 153.0m)
Net Margin = 23.54% (Net Income TTM 36.0m / Revenue TTM 153.0m)
Gross Margin = 64.60% ((Revenue TTM 153.0m - Cost of Revenue TTM 54.2m) / Revenue TTM)
Gross Margin QoQ = 68.53% (prev 69.07%)
Tobins Q-Ratio = 0.86 (Enterprise Value 1.40b / Total Assets 1.63b)
Interest Expense / Debt = 1.49% (Interest Expense 13.0m / Debt 875.3m)
Taxrate = 3.81% (281.0k / 7.38m)
NOPAT = 119.7m (EBIT 124.4m * (1 - 3.81%))
Current Ratio = 0.89 (Total Current Assets 21.0m / Total Current Liabilities 23.5m)
Debt / Equity = 1.23 (Debt 875.3m / totalStockholderEquity, last quarter 714.1m)
Debt / EBITDA = 23.32 (Net Debt 869.5m / EBITDA 37.3m)
Debt / FCF = 23.44 (Net Debt 869.5m / FCF TTM 37.1m)
Total Stockholder Equity = 726.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.20% (Net Income 36.0m / Total Assets 1.63b)
RoE = 4.96% (Net Income TTM 36.0m / Total Stockholder Equity 726.6m)
RoCE = 7.75% (EBIT 124.4m / Capital Employed (Total Assets 1.63b - Current Liab 23.5m))
RoIC = 7.42% (NOPAT 119.7m / Invested Capital 1.61b)
WACC = 4.15% (E(532.3m)/V(1.41b) * Re(8.61%) + D(875.3m)/V(1.41b) * Rd(1.49%) * (1-Tc(0.04)))
Discount Rate = 8.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.16%
[DCF Debug] Terminal Value 87.27% ; FCFF base≈62.6m ; Y1≈69.2m ; Y5≈89.6m
Fair Price DCF = 47.95 (EV 2.64b - Net Debt 869.5m = Equity 1.77b / Shares 37.0m; r=5.90% [WACC]; 5y FCF grow 12.13% → 2.90% )
EPS Correlation: -33.19 | EPS CAGR: -45.65% | SUE: -4.0 | # QB: 0
Revenue Correlation: 65.61 | Revenue CAGR: 23.65% | SUE: -0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.41 | Chg30d=-0.018 | Revisions Net=-3 | Analysts=6
EPS next Year (2026-12-31): EPS=1.59 | Chg30d=-0.067 | Revisions Net=-3 | Growth EPS=-10.9% | Growth Revenue=-6.5%

Additional Sources for CCAP Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle